Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 11:46 AM
Ignite Modification Date:
2025-12-26 @ 11:46 AM
NCT ID:
NCT00086216
Eligibility Criteria:
Inclusion Criteria:
* documented history of multiple myeloma,
* failed at least two prior regimens for multiple myeloma,
* 18 years of age or older,
* ECOG(Zubrod)PS of 0 to 2,
* screening evaluation for determining eligibility prior to enrollment,
* signed informed consent form,
Exclusion Criteria:
* concomitant therapy medications including corticosteroids or other chemotherapy that is or may be active against myeloma ,
* renal insufficiency (serum creatinine levels of \> 2mg/dL),
* mucosal bleeding,
* any condition which in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study.
* clinically relevant active infection or co-morbid medical conditions.
* prior malignancy(within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient is has been disease-free for at least 3 years.
* patients with non-secretory myeloma.
* as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be excluded.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00086216
Study Brief:
Protocol Section:
NCT00086216